{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:21:49Z","timestamp":1788787309986,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clon.2023.09.012","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:40:31Z","timestamp":1695814831000},"page":"e676-e688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography\/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"35","author":[{"given":"J.D.","family":"Subiela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gomis Sell\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lopez Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Aumatell Ovide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Ajuria Illarramendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Gonz\u00e1lez-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gajate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Ortega Polledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Alonso y Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"G\u00f3mez Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rodr\u00edguez-Patr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Burgos Revilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clon.2023.09.012_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020 Update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clon.2023.09.012_bib2","first-page":"1288","article-title":"NCCN Guidelines(R) Insights: Prostate cancer, Version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.clon.2023.09.012_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clon.2023.09.012_bib4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2023.09.012_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1748-717X-9-42","article-title":"Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir","volume":"9","author":"Anwar","year":"2014","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.clon.2023.09.012_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","article-title":"SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer","volume":"6","author":"Kishan","year":"2016","journal-title":"Pract Radiat Oncol"},{"issue":"7","key":"10.1016\/j.clon.2023.09.012_bib7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41416-020-0978-4","article-title":"The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer","volume":"123","author":"Noble","year":"2020","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clon.2023.09.012_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/rg.2020190121","article-title":"Current imaging techniques for and imaging spectrum of prostate cancer recurrence and metastasis: a pictorial review","volume":"40","author":"Tanaka","year":"2020","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.clon.2023.09.012_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clon.2023.09.012_bib10","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.09.012_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.clon.2023.09.012_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.clon.2023.09.012_bib13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.2967\/jnumed.121.262861","article-title":"18)F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after curative-intent radiation therapy: a bicentric retrospective study","volume":"63","author":"Ilhan","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.clon.2023.09.012_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.euo.2020.01.002","article-title":"Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix criteria for biochemical recurrence after curative radiotherapy","volume":"4","author":"Jansen","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clon.2023.09.012_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2022.02.014","article-title":"Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: implications for potential salvage","volume":"169","author":"Maitre","year":"2022","journal-title":"Radiother Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.clon.2023.09.012_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bju.13616","article-title":"The use of (68) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer","volume":"118","author":"Meredith","year":"2016","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clon.2023.09.012_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41391-019-0163-0","article-title":"The use of (68)Ga-PET\/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy","volume":"22","author":"Raveenthiran","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.clon.2023.09.012_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2967\/jnumed.117.190157","article-title":"68)Ga or (18)F for prostate cancer imaging?","volume":"58","author":"Kesch","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.clon.2023.09.012_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.119.234187","article-title":"Head-to-head comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard","volume":"61","author":"Kuten","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.clon.2023.09.012_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2967\/jnumed.119.229187","article-title":"Matched-pair comparison of (68)Ga-PSMA-11 PET\/CT and (18)F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"13","key":"10.1016\/j.clon.2023.09.012_bib21","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","article-title":"Clinical insignificance of [(18)F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation","volume":"48","author":"Arnfield","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.clon.2023.09.012_bib22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clon.2023.09.012_bib23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A\u00a0systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2023.09.012_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/EDBK_239041","article-title":"Oligometastatic prostate cancer: a shrinking subset or an opportunity for cure?","volume":"39","author":"Rao","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.clon.2023.09.012_bib25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.clon.2023.09.012_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2023.09.012_bib27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clon.2023.09.012_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/COC.0000000000000635","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer recurrence: a meta-analysis","volume":"43","author":"Viani","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2023.09.012_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-020-04945-1","article-title":"False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial","volume":"48","author":"Fendler","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523003333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523003333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:53:31Z","timestamp":1760543611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655523003333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0936655523003333"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2023.09.012","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography\/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2023.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}